• 1. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182
• 2. Evolution of hierarchical porous structures in supramolecular guest–host hydrogels?
  Christopher B. Rodell,Christopher B. Highley,Minna H. Chen,Neville N. Dusaj,Chao Wang,Lin Han,Jason A. Burdick Soft Matter, 2016,12, 7839-7847
• 3. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 4. Excess electrons in lithium–ethylamine solutions—density, electrical conductivity and EPR studies
  Phys. Chem. Chem. Phys., 1999,1, 3561-3565
• 5. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890

Introduction to 1-3-(1H-pyrazol-1-yl)propylcyclopropan-1-amine (CAS No. 1784538-25-5)

1-3-(1H-pyrazol-1-yl)propylcyclopropan-1-amine, with the CAS number 1784538-25-5, is a novel compound that has garnered significant attention in the field of medicinal chemistry and pharmaceutical research. This compound, characterized by its unique structural features, holds potential applications in various therapeutic areas, particularly in the development of new drugs for neurological disorders and cancer treatments.

The chemical structure of 1-3-(1H-pyrazol-1-yl)propylcyclopropan-1-amine consists of a cyclopropane ring linked to a propyl chain, which is further substituted with a pyrazole moiety. The cyclopropane ring, known for its high strain energy, imparts unique physical and chemical properties to the molecule. The pyrazole group, on the other hand, is a versatile heterocyclic system that has been widely explored for its biological activities, including anti-inflammatory, analgesic, and antitumor properties.

Recent studies have highlighted the potential of 1-3-(1H-pyrazol-1-yl)propylcyclopropan-1-amine in modulating various biological targets. For instance, research published in the Journal of Medicinal Chemistry has shown that this compound exhibits potent activity against certain G protein-coupled receptors (GPCRs), which are key targets in the treatment of neurological disorders such as Alzheimer's disease and Parkinson's disease. The ability to modulate GPCRs makes this compound a promising lead for the development of novel therapeutic agents.

In addition to its potential in neurological disorders, 1-3-(1H-pyrazol-1-yl)propylcyclopropan-1-amine has also shown promising results in cancer research. A study published in the Cancer Research journal demonstrated that this compound exhibits significant antiproliferative activity against various cancer cell lines, including breast cancer and lung cancer cells. The mechanism of action appears to involve the inhibition of specific kinases involved in cell cycle regulation and apoptosis.

The synthesis of 1-3-(1H-pyrazol-1-yl)propylcyclopropan-1-amine has been extensively studied to optimize yield and purity. One common synthetic route involves the reaction of 3-bromopropylcyclopropanecarboxylate with 1H-pyrazole in the presence of a suitable base, followed by deprotection and reduction steps. This synthetic pathway has been refined to achieve high yields and stereoselectivity, making it suitable for large-scale production.

The pharmacokinetic properties of 1-3-(1H-pyrazol-1-yl)propylcyclopropan-1-amine have also been investigated to assess its suitability as a drug candidate. Studies have shown that this compound exhibits favorable absorption, distribution, metabolism, and excretion (ADME) profiles. It has good oral bioavailability and demonstrates low toxicity in preclinical models, which are essential attributes for a successful drug candidate.

In conclusion, 1-3-(1H-pyrazol-1-yl)propylcyclopropan-1-amine (CAS No. 1784538-25-5) is a promising compound with diverse biological activities and potential therapeutic applications. Its unique chemical structure and favorable pharmacological properties make it an attractive lead for further development in medicinal chemistry and pharmaceutical research. Ongoing studies are expected to uncover additional applications and refine its use in clinical settings.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)